With Higher Specificity, Alzinova’s Vaccine Candidate Offers a New Approach to Tackle Alzheimer’s Disease

Date: 2022-01-05

The European Medicines Agency (EMA) recently recommended the refusal of the marketing authorisation for Aduhelm, a medicine intended for the treatment of Alzheimer’s disease.

“At the same time, the Swedish research company Alzinova is working to offer a better, more specific and effective treatment alternative” – Read more in the BioStock-article below.

Link to BioStock Article (in Swedish)

For more information in English, see Our Progams-web page.